Effects of Coenzyme Q10 in PSP and CBD

Last updated: June 14, 2018
Sponsor: Lahey Clinic
Overall Status: Completed

Phase

2/3

Condition

Progressive Supranuclear Palsy

Neuronal Ceroid Lipofuscinoses (Ncl)

Dystonias

Treatment

N/A

Clinical Study ID

NCT00532571
CoQ10 with PSP/CBD
  • Ages > 40
  • All Genders

Study Summary

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who werediagnosed within the past 5 years

  • Age > 40

  • Subjects receiving anticholinergics, amantadine, dopamine agonists,carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 daysprior to baseline visit.

  • Patients agreeable to participate in the study.

Exclusion

Exclusion Criteria:

  • Prior or concurrent therapy with anticholinergics, amantadine,a dopamineagonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.

  • Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.

  • History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissuetransplant.

  • Previous use of coenzyme Q10 within 60 days of the baseline visit.

Study Design

Study Start date:
January 01, 2004
Estimated Completion Date:
September 30, 2005

Connect with a study center

  • Lahey Clinic

    Burlington, Massachusetts 01805
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.